USA's CBO revises estimate of the budgetary effects of the Senate-passed Health Bill

17 March 2010

The USA's Congressional Budget Office (CBO) has just released an estimate of the budgetary effects of the health bill, HR 3590, that passed the Senate on December 24, 2009, which differs from the estimate for a slightly earlier version of the legislation that was released on December 19 last year.

The CBO and the Joint Committee on Taxation (JCT) now estimate that, on balance, the direct (mandatory) spending and revenue effects of enacting HR 3590 as passed by the Senate would yield a net reduction in federal deficits of $118 billion over the 2010-2019 period. (Direct spending - as distinguished from discretionary spending - is spending that stems from legislation other than appropriation acts.). In their earlier estimate, the budgetary impact was a net reduction in deficits of $132 billion.

The gross cost of the proposed expansions in insurance coverage over those 10 years is now projected to be $875 billion, reflecting subsidies provided through insurance exchanges, increased net outlays for Medicaid and the Children's Health Insurance Program (CHIP), and tax credits for small employers. Those costs are partly offset by revenues from an excise tax on high-premium insurance plans and net savings from other coverage-related sources, leaving a net cost of $624 billion for the coverage provisions. Other provisions affecting direct spending save $478 billion, on net - mostly in Medicare - and other provisions affecting revenues reduce the deficit by $264 billion, on net. Thus, the net effect on deficits of the bill as a whole equals $624 billion less $478 billion less $264 billion, or a reduction of $118 billion over the 2010-2019 period. In total, the CBO and JCT estimate that the legislation would increase outlays by $355 billion and raise revenues by $473 billion between 2010 and 2019.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical